|
Home
|
E-Submission
|
Sitemap
|
Editorial Office
|
Aims and Scope
About the Journal
Editorial Board
Open Access
Best Reviewer Awardees
Article Processing Charge
Editorial Office
Instructions for Authors
Research and Publication Ethics
Checklist
E-Submission
Copyright Transfer Agreement
All issues
Accepted Articles
Epub Ahead-of Print Articles
Current Issue
Most Read Articles
Most Cited Articles
Cancer Research and Treatment
Search
Author Index
Cancer Research and Treatment
Search
> Browse Articles > Search
Lung and Thoracic cancer
First-Line Alectinib vs. Brigatinib in Advanced Non–Small Cell Lung Cancer with
ALK
Rearrangement: Real-World Data
Youngkyung Jeon, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Cancer Res Treat.
2024;56(1):61-69. Published online July 14, 2023 DOI:
https://doi.org/10.4143/crt.2023.461
Crossref 1
Sarcoma
Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single-Center Study
Xin Liu, Chengcheng Gong, Jieyun Zhang, Wanjing Feng, Yanjing Guo, Youzhou Sang, Chunmeng Wang, Yong Chen, Jian Wang, Lin Yu, Xiaowei Zhang, Zhiguo Luo
Cancer Res Treat.
2023;55(3):1001-1010. Published online March 3, 2023 DOI:
https://doi.org/10.4143/crt.2022.894
Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing
Eunhyang Park, Hyo Sup Shim
Cancer Res Treat.
2020;52(2):543-551. Published online November 8, 2019 DOI:
https://doi.org/10.4143/crt.2019.305
Web of Science 15
Crossref 13
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
Su-Jung Kim, Soyeon Kim, Dong-Wan Kim, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yusoo Lee, Jaemoon Koh, Yoon Kyung Jeon, Dae Seog Heo
Cancer Res Treat.
2019;51(3):1231-1240. Published online December 31, 2018 DOI:
https://doi.org/10.4143/crt.2018.486
Web of Science 18
Crossref 16
Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of
Anaplastic Lymphoma Kinase
‒Positive Anaplastic Large Cell Lymphoma
Wendan Xu, Ji-Won Kim, Woo June Jung, Youngil Koh, Sung-Soo Yoon
Cancer Res Treat.
2018;50(2):599-613. Published online June 19, 2017 DOI:
https://doi.org/10.4143/crt.2016.357
Web of Science 7
Crossref 6
ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor
Ji Won Lee, Sung Hye Park, Hyoung Jin Kang, Kyung Duk Park, Hee Young Shin, Hyo Seop Ahn
Cancer Res Treat.
2018;50(2):495-505. Published online May 22, 2017 DOI:
https://doi.org/10.4143/crt.2016.577
Web of Science 9
Crossref 11
SEC31A-ALK
Fusion Gene in Lung Adenocarcinoma
Ryong Nam Kim, Yoon-La Choi, Mi-Sook Lee, Maruja E. Lira, Mao Mao, Derrick Mann, Joshua Stahl, Abel Licon, So Jung Choi, Michael Van Vrancken, Joungho Han, Iwona Wlodarska, Jhingook Kim
Cancer Res Treat.
2016;48(1):398-402. Published online February 17, 2015 DOI:
https://doi.org/10.4143/crt.2014.254
Web of Science 23
Crossref 21
The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
June-Koo Lee, Dong-Wan Kim, Bhumsuk Keam, Tae Min Kim, Se-Hoon Lee, Young-Joo Kim, Dae Seog Heo
Cancer Res Treat.
2015;47(2):182-188. Published online September 12, 2014 DOI:
https://doi.org/10.4143/crt.2013.227
Web of Science 4
Crossref 2
1
Journal Impact Factor 4.6
> Browse Articles > Search
